Solventum (NYSE:SOLV - Free Report) had its price target increased by The Goldman Sachs Group from $63.00 to $71.00 in a research note published on Monday,Benzinga reports. The brokerage currently has a sell rating on the stock.
Other analysts have also issued reports about the stock. Morgan Stanley upped their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. Wells Fargo & Company upped their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. Piper Sandler lifted their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a report on Friday, February 28th. Mizuho started coverage on Solventum in a report on Wednesday, December 4th. They set a "neutral" rating and a $70.00 target price for the company. Finally, Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $79.86.
Read Our Latest Research Report on SOLV
Solventum Stock Down 2.8 %
NYSE SOLV traded down $2.14 on Monday, reaching $75.69. 1,066,177 shares of the stock traded hands, compared to its average volume of 1,444,759. Solventum has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a fifty day moving average price of $73.25 and a 200-day moving average price of $70.39. The company has a market cap of $13.08 billion and a price-to-earnings ratio of 27.52.
Institutional Trading of Solventum
A number of institutional investors have recently made changes to their positions in SOLV. Modus Advisors LLC purchased a new stake in Solventum in the fourth quarter valued at about $25,000. Clarity Asset Management Inc. purchased a new position in shares of Solventum in the 4th quarter valued at approximately $25,000. Stonebridge Financial Group LLC acquired a new stake in Solventum in the 4th quarter worth approximately $26,000. Raiffeisen Bank International AG purchased a new stake in Solventum during the 4th quarter worth approximately $29,000. Finally, Crews Bank & Trust purchased a new stake in Solventum during the 4th quarter worth approximately $32,000.
About Solventum
(
Get Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
